KERSIO LUX - KERSIO EQUITY A EUR ACC

FEBRUARY 2019 ESMA RISK LEVEL²: 1 2 3 4 5 6 7

Investment Policu

The objective of the fund is to offer to investors a return generated by a diversified portfolio of companies of large, medium and small capitalization listed on the main organized markets of the OECD. The fund is aimed at investors who wish to obtain adequate returns with a reasonable risk. The methodology for selecting companies includes an analysis of the fundamental parameters and a qualitative study of each company.

This reference of the policy is an extract of it, the investor can consult it all information in the DFI / KIID of the fund.



Rentabilidades pasadas no garantizan rentabilidades futuras.

Historical perfomance / returns

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year	
Fund					1.40%	1.00%	-0.73%	-1.42%	1.30%	1.46%	-2.46%	2.96%	2017	3.44%
Benchmark					-2.40%	-3.17%	0.22%	-0.81%	5.07%	2.20%	-2.83%	-1.85%		-3.79%
Fund	2.53%	2.39%	1.29%	4.01%	-0.45%	0.17%	5.00%	-0.37%	1.06%	-5.76%	-3.26%	-7.12%	2018	-1.26%
Benchmark	3.01%	-4.72%	-2.25%	5.21%	-3.67%	-0.32%	3.83%	-3.76%	0.19%	-5.93%	-0.76%	-5.41%		-14.34%
Fund	10.04%	0.93%											2019	11.06%
Benchmark	5.26%	4.39%												9.89%

Fund details

Category	International Equity
Benchmark	EUROSTOXX 50
ISIN	LU1476746869
Investment Manager	UBS Fund Management (Luxembourg) S.A.
Custodian	UBS Europe SE, Luxembourg branch
Auditor	Ernst & Young
Currency	EUR

AUM

NAV		113.44 €	
Total A	ssets under management	-	

FPPS

Management fees	0,72%
Custodian/ Depositary fees	0,049%

Returns / performance

3.56%
-5.10%
4.46%

Fund Manager Comment

In February the markets have been very strong again, as they were in January. During these two first months of the year, the index SX5T or Eurostoxx50 with dividends, our benchmark, has soared at an accumulated pace of 10,16%. Still, Kersio Lux, greatly due to its outstanding performance during the first month of the year, has beaten the index with a total increase of 11,06%. This, which is ninety percentage points above, is specially noteworthy taking into account that our beta is clearly less than 1, so our alpha is really very satisfactory.

In Feburary we have continued rebalancing our positions, selling partially some shares like HCA, a US health firm which has excellent fundamentals but has risen so much that the weight in the portfolio made advisable some reduction. Although it is clear to us that the European shares will weigh always more than 50% of the portfolio, we are still finding good opportunities both in the US and the Canadian market, which we are exploring thoroughfully.

The information contained in this presentation is provided for information purposes only and should in no event be construed as a solicitation or offer, as advice or as a recommendation to buy, sell or engage in any transaction whatsoever. The information and data contained in this document have been obtained from sources believed to be reliable, but they are not guaranteed. All expressions of opinion are subject to change without notice and are not intended to be a guarantee of future events. Neither accuracy nor completeness is warranted and any liability, including incidental or consequential damages, arising from errors or omissions in this document are expressly disclaimed. It is the responsibility of any person to comply with the laws of the country in which he is resident and/or using the service and that person will bear any direct or indirect consequences resulting from non-compliance with these legal and regulatory requirements. Subscriptions in the Company's Shares are only valid if they are made in accordance with the provisions of the Prospectus and the key investor information document(s) accompanied by the most recent annual report available and, in addition, by the most recent half-year report if this was published after the most recent annual report. No one may make use of information other than that appearing in the Prospectus or the key investor information document and in the documents mentioned therein as being available for consultation by the public. Investors should choose the Sub-Fund that best suits their specific risk and return expectations as well as their diversification needs and are encouraged to seek independent advice in that regard. Past performance is not a guide